Over the last several decades, improved awareness of the prevalence of carcinogens in the environment, along with a growing appreciation of the complexity of the carcinogenesis process, has shifted policy on cancer risk from one of strict avoidance of carcinogens to one of adherence to exposure limits deemed 'safe' based on quantitative risk estimation. Meanwhile, given the mutagenic nature of most carcinogens, attention has gravitated to developing a genetic rationale for measuring and comparing risks. This focus has culminated in the now well-established multistage mutational paradigm, which holds that a stepwise sequence of mutations drives cell "initiation" and the subsequent "transformation" of an initiated cell into a cancer cell, and that, once created, a cancer cell will inevitably undergo "progression" to become overt disease. Relatively unappreciated is the effect progression-phase population- Author Manuscript Published OnlineFirst on DOI: 10.1158/0008-5472.CAN-13-2508 The issue of cancer risk from exposure to environmental carcinogens impacts millions of individuals worldwide. Policy considerations include the setting of appropriate standards for exposure in the workplace, home and clinic, along with assessing tradeoffs among alternative energy sources and classifying carcinogens to which the public may be exposed. Of special interest to the U.S. Dept. of Energy (DOE) is the cancer risk associated with the post-Cold-War cleanup of nuclear waste; more generally, the longstanding question of whether there exist radiation dose or dose-rate thresholds below which there is no increase, or perhaps even a decrease, in cancer risk (1, 2). The National Aeronautics and Space Administration (NASA) seeks to estimate the excess radiogenic cancer risk from long-duration space missions (3, 4).
The issue of cancer risk from exposure to environmental carcinogens impacts millions of individuals worldwide. Policy considerations include the setting of appropriate standards for exposure in the workplace, home and clinic, along with assessing tradeoffs among alternative energy sources and classifying carcinogens to which the public may be exposed. Of special interest to the U.S. Dept. of Energy (DOE) is the cancer risk associated with the post-Cold-War cleanup of nuclear waste; more generally, the longstanding question of whether there exist radiation dose or dose-rate thresholds below which there is no increase, or perhaps even a decrease, in cancer risk (1, 2) . The National Aeronautics and Space Administration (NASA) seeks to estimate the excess radiogenic cancer risk from long-duration space missions (3, 4) .
In response to workplace concerns, the National Institute for Occupational Safety and Health (NIOSH) upgraded an earlier policy that called for "no detectable exposure levels for proven carcinogenic substances" (5) . It now recommends chemical carcinogen exposure limits go beyond 'no effects' to include exposure levels at which there may be residual risks. RISC-RAD, an 11-country project funded by the European Commission, is dedicated to understanding carcinogenesis risk "at low doses and dose rates and the effects of radiation quality at exposures below those at which direct information is available". With the now widespread implementation of airport x-ray backscatter screening procedures and the highprofile Fukushima nuclear power plant disaster, considerable public attention has been drawn to these issues.
In parallel with these developments, efforts have been underway to fully understand the events leading to cancer cell generation. Carcinogenesis, the sequence of events that convert a normal cell into an expanding, invasive neoplastic mass, is commonly modeled as initially involving a series of cell mutations followed by clonal expansions (6, 7). These so-called "natural history" models of carcinogenesis take on various forms, but are inspired by the basic two-stage mutational paradigm. By this paradigm, a chance DNA-altering event (e.g., a point mutation, deletion, translocation, copy number change, or heritable epigenetic alteration)
"initiates" a cell, i.e., alters its growth characteristics and predisposes it for later carcinogenic conversion. In a phase called "promotion", the progeny of this initiated cell go on to display modified growth characteristics and altered propensities to undergo further spontaneous or induced genetic change. This cycle of DNA alteration and clonal expansion is revisited a number of times. Ultimately, a cell in the clone undergoes a "transformation" event, becoming a frank cancer cell, which expands within the host tissues to become overt disease ( Figure 1 ).
As carcinogenesis proceeds, what begins as a cell-level series of events graduates to include population-level effects shortly after initiation, then comes to include tissue-level influences as the nascent tumor grows and acquires larger-scale properties e.g. invasiveness and metastatic potential, upon interaction with the host.
Work in colon carcinogenesis has refined our understanding of the malignant transformation event. It is known, for instance, that sequential mutations of key genes, adenomatous polyposis coli (APC), Ras/Raf, and p53, can transform a colonic crypt cell (8) . After a cancer cell is created, the progeny population evolves over a phase termed progression, during which a number of the characteristic features of cancer, e.g., tumor angiogenesis, resistance to cell death and insensitivity to growth-inhibitory signaling, are acquired or enhanced (9) . But the rapid accumulation of these and other molecular insights into carcinogenesis gained over the last 50 years would only gradually win favor for mechanistic risk modeling to become the guide for public policy on carcinogen exposure. With the renaissance in attitude that took place in the late 1970's, a 'precautionary principle' that arbitrarily sought exposure limits well below the No Observed Adverse Effect Level (NOAEL), finally gave way to a 'quantitative risk assessment' objective that made experimentation and elucidation of molecular mechanism the gold standard (10) .
But while the embrace of molecular mechanism for risk-based policymaking is now the mainstay, unexpected challenges to the carcinogenesis paradigm itself have begun to surface.
As a case in point, research into cancer risk from radiation exposures in the low-dose realm is tackling the perplexing question of whether the risk at very low doses remains doseproportional (11), or instead deviates higher (12) or lower (13) , perhaps to the point where the risk is actually reduced (14) . However this plays out, these investigations have served to bring to the risk modeling forefront a growing sentiment that the multistage mutational paradigm, with the rather simplistic monotonic association it makes between cellular DNA damage and risk, neglects contributions from other biological scales of influence.
Complicating matters further, mechanistic insights into carcinogenesis are frequently derived indirectly from the study of cellular and molecular 'surrogates' expected to correlate with cancer risk, e.g., the extent of DNA damage and repair, oxidative stress, and genomic instability (15) (16) (17) . Likewise, at the other end of the spectrum, conclusions as to how cells advance through the steps leading to cancer presentation are inferred from epidemiologic data on cancer incidence (18) in connection with cell culture and animal natural history models of tumor development (19, 20) . Amidst the various linkages thus made, one presumption that has been consistently applied from the multistage mutational paradigm is that a cancer cell, once created, will eventually manifest as a cancer case (6, (21) (22) (23) . By this standard, once a cell transforms to become a cancer cell, its progression to manifest disease is inevitable and the risk of eventual cancer incidence certain (left curve, Figure 2 ).
Countering this notion, a vast number of direct observations at the level of tumor progression are showing interactions of cancer cells with themselves and with cells of the host, may not only promote, but also slow, stop or even reverse a carcinogenesis course (24) (25) (26) (27) (28) (29) (30) . One is confronted with the realization that cancer risk determination from exposures to carcinogenic agents not only requires a multi-scale effort to link the various levels at which data are available (from molecular to cellular to tissue to epidemiologic), but that the risk itself is influenced at multiple scales, having substantial population-and tissue-level components The failure of the cancer cell aggregate to mobilize host cooperation, or to evade host suppression, may cause the cancer to halt its progression, or even regress (45) . In this regard, those key host processes that require modification to permit cancer progression amount to "bottlenecks", the surmounting of which is essential for cancer incidence. The failure of cancer cells to recruit blood vessels and to overcome host immune surveillance, constitute two common progression-level bottlenecks, either of which could hold a tumor in a dormant state for an extended period (46) (47) (48) . Recently, we have shown in murine studies that even host age itself (49) individuals dying of non-cancer causes. Once thought anomalous, 'dormant' cancers were shown to be more the rule than the exception, with the discovery that most 'cancer-free' individuals harbor small, indolent tumor lesions that will not progress to manifest disease (25, 27, 50, 51) . These and other findings have raised the concern that as our ability to screen for cancer improves, so will our tendency to treat lesions that pose no threat (51, 52) . Reinforcing this point, although lethal lung cancer is 10 times more common in smokers, spiral CT screening is revealing non-smokers have about the same number of lung lesions as smokers (53, 54) . More generally, constraints imposed on cancer stem cell expansion by non-stem cancer cells may also retard tumor growth (42) . In this setting, non-stem cancer cell death is paradoxically seen to speed up overall tumor growth, while the presence of non-stem cancer cells slows overall growth. The potentially systemic reach of mediation of tumor progression is supported by the finding that methionine metabolism, done primarily by the liver, correlates strongly with prostate cancer recurrence after radical prostatectomy (69) . While a direct connection is not yet clear, that a fundamental metabolic pathway should be so intertwined with cancer progression offers highly suggestive evidence that cancer progression is a system-level process having system-level controls.
The emerging realization is that cancer development entails not just negotiating processes en route to producing a cancer cell population, but involves larger-scale population-, tissue-and organism-scale influences that accelerate or suppress progression of the nascent cancer population. This realization has major ramifications for carcinogenesis risk estimation and the development of countermeasures. In particular, it contradicts the common presumption in risk analysis of a direct coupling between the molecular steps in cellular oncogenesis leading up to transformation, and the final epidemiologic endpoint of cancer incidence (left curve, Figure 2 ).
The critical roles of post-transformational cell-cell and cell-host interactions as "tissue-scale checkpoints" -potential barriers to tumor advancement -have begun to be appreciated in principle, but remain to be incorporated in quantitative modeling constructs as pivotal risk modifiers (right curve, Figure 2 ). Of specific concern here is that, since the effects of any progression-level bottlenecks on tumor advancement are already folded into the epidemiological data, risk models that ignore these inputs by assuming cancer incidence is inevitable once cancer cells are created, cannot correctly back-infer the cancer's 'natural history' (i.e., the mutational, population-level, and host-interactive steps leading up to cancer incidence). In such analytic models, any reduction in tumor incidence due to such bottlenecks to tumor advancement will necessarily be taken into account through an inappropriate inflation of the estimated number of pre-transformation mutational events necessary to create the first cancer cell.
To avoid this disparity, it is clear there is a need to better interface biologically-based mechanistic carcinogenesis models with both natural history models and their epidemiologic cancer incidence endpoints. Meanwhile, research into the role of post-transformational mechanisms in cancer development is proceeding at a rapid pace. With it, a broadened picture of tumor progression is emerging that awaits integration into existing carcinogenesis models to provide improved risk assessments. In particular, the recognition that dormant microscopic tumors are highly prevalent in the population is poised to add a clear and (72) . This contrasts with tumor-cell-centric thinking on this point, which has posited such potential is only acquired gradually through mutation over the course of cancer development (72) . Rounding out this picture, the physical and molecular determinants of altered stromal signaling (28), a permissive angiogenic state (41), environmentally-modified cancer stem cell kinetics (42, 43) , the role of recruited cells in aiding cancer stem cells to drive tumor development (44) , and aspects of the immune response that facilitate tumor progression (56, 57) are being elucidated.
Looking ahead, as the traditional considerations of intra-cellular, molecular-scale hallmarks of carcinogenesis are joined through modeling with consideration of the equally influential roles played by multiple tissue-scale bottlenecks -endpoints that tend also to be macroscopic and thus potentially easier to track -the relative roles of these intra-cellular molecular events will be more properly contextualized. Risk projections stemming from such multi-scale modeling efforts would not only better inform policy, but help in the identification of additional therapeutic control points in cancer development. 
